We have drugs that lower visceral fat (Thiazolidinediones)
They are used for diabetes
I wonder if low/micro dose could be used to lower visceral fat in non diabetics and lead to better cardiometabolic outcomes
Surely there’s a biohacker somewhere that thought of this?